High-pressure fibrin sealant foam: an effective hemostatic agent for treating severe parenchymal hemorrhage.

Background: The majority of early trauma deaths are related to uncontrolled, noncompressible, parenchymal hemorrhage from truncal injuries. The purpose of this study was to formulate a fibrin sealant foam (FSF) able to control severe parenchymal bleeding without compression or vascular control.

Materials And Methods: FSF with high fibrinogen concentration (20 mg/mL) and low thrombin activity (5 U/mL) was prepared and pressurized by addition of liquid gas propellant.

Comparative study of the hemostatic efficacy of a new human fibrin sealant: is an antifibrinolytic agent necessary?

Background: Sustained hemostasis by fibrin sealant (FS) is critically important when it is used in trauma surgery. To purportedly delay fibrin degradation and prevent premature hemostatic failure, some FS products added an antifibrinolytic agent (e.g.